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Proteoglycans are hybrid molecules composed of a
core protein and covalently attached glycosamino-
glycan chain(s). The structure, location, and proces-
sing of these molecules enables them to encode
speci®c information that is used in multiple physio-
logic processes. Endothelial cells in the skin are in¯u-
enced by proteoglycans through binding interactions
between glycosaminoglycans and extracellular
matrix, growth factors, cytokines, adhesion recep-
tors, enzymes, and enzyme inhibitors. In wound
repair, proteoglycans such as the syndecans are
induced by antimicrobial peptides and can control
growth factor responsiveness. The glycosaminogly-
cans further signal endothelial cells to increase
expression of ICAM-1 and other molecules impor-
tant for leukocyte adhesion. Thus, proteoglycans
represent a powerful central regulatory element in
skin that in¯uences a wide variety of events and par-
ticipates in host defense and tissue repair. Key words:
dermatan sulfate/hair development/heparan sulfate/synde-
can/wound repair. Journal of Investigative Dermatology
Symposium Proceedings 5:55±60, 2000
T
here is a long history of observations regarding the
composition and dynamic changes that take place in
the proteoglycans of the skin. Despite this, the
technical dif®culties faced when working with these
molecules has left them poorly understood. Over the
last decade work in several converging ®elds has greatly advanced
information about proteoglycans, and their components the
glycosaminoglycans (GAG). This work has identi®ed proteoglycans
and GAG as critical for growth factor responsiveness, cell adhesion,
tissue remodeling, and immune defense. Each of these functions
relies on the unique properties of proteoglycans and on the
extensive inter and intracellular enzymatic modi®cations that must
take place in order to process GAG into functional molecules.
Current understanding suggests vascular cell biology is particularly
strongly in¯uenced by proteoglycans and GAG, and that the
process of wound repair is an excellent model system to illustrate
the importance of these molecules to skin biology.
THE INFORMATION CODE OF A
GLYCOSAMINOGLYCAN AND PROTEOGLYCAN
A proteoglycan is a hybrid molecule composed of a central core
protein to which one or more GAG are covalently attached (for
reviews see Jackson et al, 1991; Gallo and Bern®eld, 1995; Lander,
1998; Iozzo, 1998; Woods and Couchman, 1998). The proteogly-
cans have a unique strategy to transmit information. Functional
information is encoded in the sequence of amino acids of the core
protein, in the sequence of sugars in the GAG chain, and on the
®nal enzymatic processing of the proteoglycan or GAG in the
tissue. Thus, critical to the understanding of the function of these
molecules is familiarity with the elements within these molecules
that are used to encode their unique functional properties.
GAG are understood based on the sequence and structures of the
disaccharides found within each. GAG are known as heparan
sulfate, chondroitin sulfate A, chondroitin sulfate B, chondroitin
sulfate C, keratan sulfate, and hyaluronic acid. Hyaluronic acid
contains a glucuronic acid alternating with N-acetylglucosamine
linked b1±3 and b1±4, is not sulfated, and is not covalently attached
to core proteins. Keratan sulfate contains galactose alternating with
N-acetylglucosamine linked b1±4 and b1±3. Chondroitin sulfates
contain glucuronic acid alternating with N-acetyl galactosamine
linked b1±3 and b1±4. In chondroitin sulfate B, the major GAG
present in the skin (also known as dermatan sulfate), many
glucuronic acids undergo an isomerization reaction to iduronic
acids. Finally, heparan sulfate contains iduronic or glucuronic acids
alternating with N-acetylglucosamine linked b1±4. Each of the
GAG can vary in size from only a few disaccharides to thousands,
thus the mass of these polymers may vary from as little as a few
thousand daltons to over 107 for hyaluronic acid. With the
exception of hyaluronic acid, complexity in the GAG chain is
further increased by varying sulfation patterns. Therefore, a GAG
chain has the capacity for encoding a highly unique structural
pattern with variables that include disaccharide composition,
structure, charge, and size.
The core proteins of the proteoglycans add further informa-
tion to the complex by locating GAG to speci®c intercellular
and extracellular locations in a cell type speci®c pattern. Several
gene families encode groups of core proteins that vary widely
but have in common consensus amino acid motifs that enable
covalent linkage of the GAG chain to the protein. Several
proteins, such as CD-44, have been described as ``part-time''
proteoglycans and can be found with and without GAG
attached (Brown et al, 1991). Other proteins are found
exclusively as proteoglycans. Figure 1 illustrates the structures
of some of the best known proteoglycans. These include the
cell surface proteoglycans such as the syndecans and glypicans
(Bern®eld et al, 1992), the extracellular matrix proteoglycans
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such as the small leucine-rich proteoglycans of the decorin
family and the large aggregating proteoglycans like versican, and
intracellular proteoglycans such as serglycin. Because similar
GAG can be expressed on multiple different core proteins,
expression of the core protein will in¯uence the location,
interactions, and abundance of GAG expressed. For example,
expression of syndecan-1 can direct heparan sulfate to the cell
surface, perlecan will locate heparan sulfate to the basement
membrane, and serglycin can send heparan sulfate inside a mast
cell; however, core protein expression does not exclusively
control GAG expression. When appropriately stimulated, a cell
can change the type of GAG attached to a proteoglycan core.
For example, syndecan-1 can switch from a heparan sulfate
proteoglycan to a chondroitin sulfate proteoglycan after
treatment with TGF-b (Rapraeger, 1989). In addition, enzy-
matic degradation of the proteoglycan during dynamic tissue
remodelling processes will change the location and activity of
the proteoglycan such that they can be further processed into
either active or inactive forms. Thus, proteoglycan function is
controlled by at least three separate systems; protein synthesis of
the core, GAG synthesis in the golgi, and ®nal enzymatic
reprocessing.
LOCATION OF PROTEOGLYCANS AND GAG IN THE
SKIN
Proteoglycans and GAG are present in all tissues but have a
particularly complex expression pattern in the skin. Hyaluronic acid
is synthesized in the epidermis and hyaluronan is abundantly
located here (Oksala et al, 1995). Syndecan-1 and syndecan-4 are
also abundant in the epidermis where they are expressed at the cell
surface as heparan sulfate proteoglycans (Gallo et al, 1996). In the
basement membrane, the extracellular matrix heparan sulfate
proteoglycan perlecan is most abundant (Noonan et al, 1991). In
the dermis, ®broblasts constitutively express low levels of syndecan-
4 and glypican-1 at their surface and produce extracellular matrix
proteoglycans containing dermatan sulfate such as decorin and
versican (Iozzo and Murdoch, 1996) although versican has also be
seen in the epidermis (Zimmermann et al, 1994).
Other cell types within the skin also add to the complex milieu
of proteoglycan and GAG. Mast cells synthesize large amounts of
heparan sulfate by attachment to serglycin (Stevens et al, 1988).
Neural cells express syndecan-3 (Carey et al, 1992). Endothelial
cells, which will be the focus of the functional discussion of this
review, likely have the capacity to produce multiple proteoglycans
but are best known for the expression of heparan sulfate syndecan-4
at the surface (Kojima et al, 1993).
Recognizing that the skin has multiple proteoglycans and GAG
located in a speci®c pattern illustrates the ®nding that each site
maintains a unique proteoglycan and GAG environment. Cell
behavior will be affected in speci®c ways by the components of
each of these environments. Thus, endothelial cell functions will be
modi®ed based on their expression of proteoglycans and GAG, and
by the nature of these proteoglycans and GAG in the surrounding
environment.
DEVELOPMENTAL REGULATION OF PROTEOGLYCAN
EXPRESSION
Clues to the importance of proteoglycans to cell function can be
found by study of the expression pattern of syndecans during
embryogenesis. Prior to this work a prevailing belief was that GAG
provided a structural support to tissues and primarily acted to
maintain hydration of the tissue and supported intracellular spaces.
Although this function may indeed be part of the action of GAG,
observation of dynamic shifts in proteoglycan gene expression
during critical periods of active morphogenesis suggested that these
molecules participate in processes of cell growth, differentiation,
adhesion, and movement. For example, syndecan-1 is expressed as
early as the fourth cell stage during murine embrogenesis
(Sutherland et al, 1991). As cell patterning and differentiation
progress, expression of this gene segregates to epithelial cells.
During organogenesis, cells of the invaginating epithelial placode
transiently loose syndecan-1 from their surface while the conden-
sing mesenchyme beneath the placode transiently express syndecan-
1 at high levels. Figure 2 illustrates the dynamic change in
syndecan-1 expression that occurs during hair development. This
rapid and transient switch in syndecan expression from ectodermal
tissues to mesenchyme occurs during the development of most
organs. Developmental patterning in proteoglycan expression has
been observed in many species and tends to be highly
evolutionarily conserved. Similar proteoglycan genes are known
Figure 1. Illustrations of skin proteoglycans.
Proteoglycans (PG) are present in the skin in a
variety of forms. The glycosaminoglycan side
chains are represented here as disaccharide chains
symbolized by stars, circles, and squares. The
composition of these glycosaminoglycans estab-
lishes if the proteoglycan is of the heparan sulfate
or chondroitan sulfate type. Core proteins of the
proteoglycan locate the molecule at the cell sur-
face (glypicans and syndecans), in the extracellular
space (decorin or versican), or in mast cells (ser-
glycin). Disaccharide sequence in the glycosami-
noglycan chain combined with amino acid
sequence in the core protein provides a complex
and highly effective molecule to encode informa-
tion for control of a variety of cell functions.
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in animals as evolutionarily ancient as C. elegans or drosophila
(Spring et al, 1994). Such observations suggest that proteoglycans
have a crucial role to play in the function of cells during
development.
GAG AS COFACTORS FOR GROWTH FACTOR
ACTIVITY
The adhesive properties of GAG is a principal mechanism by which
they control and modify cell function. Table I is a partial list of the
many types of molecules to which GAG will bind. Heparan sulfates
have been most extensively studied, and relatively high af®nity
constants of heparan sulfate for proteins have been recorded (i.e.,
Kd = 1±5 nM). Extensive study of this system has shown that
speci®c disaccharide sequences and sulfation patterns within
heparan sulfate are optimal for the activation of several molecules.
For example, binding to antithrombin 3 occurs by a speci®c
pentasaccharide sequence with a unique 3-O-sulfated glucosamine
(Lindahl et al, 1983). Other speci®c but distinct domains have been
identi®ed for binding to FGF-2 (Walker et al, 1994). Thus, similar
to highly speci®c protein±protein interactions, GAG±protein
binding interactions have structural speci®city encoded in the
sugar chain. It is not a regulation system that acts through simple
charge mediated adhesion of the anionic GAG to a cationic protein.
Study of the regulation of growth factor function has shown that
binding to GAG is a necessary element in the activation of many
soluble growth factors and cytokines. Best studied among the growth
factors is the activation of FGF-2 by heparan sulfate. Cells cannot
respond to FGF-2 in the absence of heparan sulfate despite the
presence of a functional FGF receptor (Rapraeger et al, 1991; Yayon
et al, 1991). When heparan sulfate is present, the complex of GAG and
FGF-2 becomes active. Recent work has solved the structure for this
complex and de®ned conformational changes that occur when FGF-
2 and GAG bind (DiGabriele et al, 1998). Further work has also
identi®ed dermatan sulfate from the skin as an alternative GAG that
can activate FGF-2 (Penc et al, 1998). Binding to GAG is a process
used by a number of proteins to control their function. GAG
associations can serve to either activate or deactivate the function of
the protein factor. Regulation of the location of proteoglycans and/or
the sequence of the GAG will therefore create an environment that
may be permissive or resistant to a complex mixture of soluble
signaling molecules. Endothelial cells in a wound, or involved in
tumor angiogenesis, will therefore be strictly limited in their
responsiveness by surrounding proteoglycan and GAG.
PROTEOGLYCANS AS CELL ADHESION MOLECULES
Many extracellular proteins bind GAG (Table I). Integral cell
surface proteoglycans such as syndecan-1 can hold a cell to the
extracellular matrix by its GAG chains. This can occur to a variety
of extracellular matrix components, including type I, III, and VI
®brillar collagen (Koda and Bern®eld, 1984; LeBaron et al, 1989),
®bronectin (Saunders and Bern®eld, 1988), thrombospondin (Sun
et al, 1989), and tenascin (Salmivirta et al, 1991). Expression of the
proteoglycan is also consistent with its role as matrix receptor.
Syndecan-1 polarizes to the basolateral surface of epithelial cells
(Jalkanen et al, 1988), and as discussed earlier localizes in early
embryogenesis to the site of matrix accumulation. In addition,
syndecan-1 and -3 colocalize with tenascin during tooth and limb
development, respectively (Solursh et al, 1990; Vainio et al, 1991).
Syndecan-1 is only expressed on pre-B cells in bone marrow and
on differentiated plasma cells in lymphoid tissues, but not when B
cell circulate (Sanderson et al, 1989) and mediates adhesion to
collagen (Ridley et al, 1993). Expression of syndecan-1 inhibits cell
invasion into type I collagen (Liebersbach and Sanderson, 1994)
and mediates cell±cell adhesion via its HS chains.
Engagement of proteoglycans with cell surface receptors or
extracellular matrix proteins is a common adhesion mechanism and
can occur through binding to the core protein or GAG. Examples
of this are seen in studies of decorin and cell surface proteoglycans
such as the syndecans. Decorin core protein stabilizes dermal
collagen structure. Deletion of this core protein by targeted
deletion of the gene results in mice whose skin has markedly
increased fragility and disorganized collagen (Danielson et al, 1997).
Interaction between cell surface HSPG such as syndecan and
®bronectin stimulates focal adhesion formation in cooperation with
integrins (Woods and Couchman, 1998). Syndecan-4 becomes
inserted into the focal adhesions of a number of cell types such as
®broblasts, smooth muscle cells, and endothelial cells (Woods and
Couchman, 1994) when protein kinase C (PKC) is activated (Oh
et al, 1997b). A unique sequence in the central part of the
cytoplasmic domain of syndecan-4 directly activates PKCa and
potentates its activity when the cytoplasmic domain is oligomerized
Figure 2. Expression of syndecan-1 in developing hair. Hair devel-
opment in the embryonic mouse was examined with a monoclonal
antibody speci®c to the mouse syndecan-1 core protein (281±2). (A) Early
ectodermal placode indicated by a white arrow is invaginating into the
underlying mesenchyme. Mesenchyme condensation is indicated with a
red arrow. Brown staining indicates syndecan-1 expression. Early epidermis
strongly expresses syndecan-1 except at the placode. Syndecan-1 is only
detected in the dermis at the condensation site. (B±D) Progressive
development of the hair bulb demonstrates continued loss of syndecan in
the developing ectoderm and expression in the condensed mesenchyme.
Scale bar: 40 mM.
Figure 3. Syndecans-1 and -4 are induced during wound repair.
Twenty-four hours after a wound to murine skin the expression of
syndecan-1 or syndecan-4 was evaluated with antibodies speci®c to each
core protein. (A) Early granulation tissue stained for syndecan-1. Syndecan-
1 is not normally detectable on endothelia or ®broblasts but intense staining
is seen in granulation tissue and on vessels in the wound. Parts (B), (C), and
(D) are adjacent sections within this granulation tissue stained for syndecan-
4 (B), syndecan-1 (C), or control isotype matched IgG (D). Red arrows
placed in vessel lumen indicate expression of syndecan on endothelia. Scale
bar: (A) 100 mM; (B±D) 20 mM.
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(Oh et al, 1997a). These examples highlight the fact that the core
protein of the proteoglycan can have speci®c functional properties
in addition to serving as a foundation for the assembly of GAG.
REGULATION OF PROTEOGLYCANS AND GAG
DURING WOUND REPAIR
Studies on wound repair in adult skin have shown the amount of
hyaluronan, sulfated GAG and proteoglycans increases in the skin
following injury (Gallo and Bern®eld, 1995). Here the potential
functional consequences of proteoglycans to vascular biology can
be most clearly seen. Several soluble factors present in the wound,
such as members of the FGF or VEGF family, PF-4, INF-g, and
AT-3, have potent effects on endothelial cells and are controlled by
binding to GAG. Changes in proteoglycan expression in this
environment will therefore in¯uence the responsiveness of blood
vessels or endothelia to these molecules. In the early phases of
wound repair endothelial cells and developing granulation tissue
show a dramatic increase in the surface expression of syndecan-1
and -4 (Fig 3). Thus, the amount of GAG attached to the cell
surface by syndecan-1 or -4 will cause cells at this site to respond
differently to the GAG-binding cytokines, growth factors, and
enzymes. Interestingly, the pattern of GAG expression after
wounding is much different in fetal human skin where hyaluronan
levels remain elevated and syndecan expression is never induced
(Gallo et al, 1996). This difference in proteoglycan expression in the
fetal wound correlates directly with a major difference in the
tendency of fetal wounds to heal without a detectable scar. Also
notable in the fetal wound is a relative lack of in¯ammatory
in®ltrate in the skin relative to newborn or adult. Thus, differences
in the expression of proteoglycans in the skin correlate with
differences in the in¯ammatory response and repair characteristics.
To test the importance of GAG expression in skin during wound
repair, GAG and proteoglycans from wounds have been puri®ed.
Wound ¯uids have abundant amounts of GAG and multiple
proteoglycans are present in a soluble form in wound ¯uid (Penc
et al, 1998). These proteoglycans include those that are normally
found in the extracellular matrix, such as decorin and versican, and
those typically seen as integral cell surface proteoglycans such as
syndecan-1 and -4 (Penc et al, 1999). As discussed earlier,
proteolytic processing of the core protein and release from the
cell surface or matrix is an additional mechanism to control location
and ability of proteoglycans. Finding these proteoglycans in the
Figure 4.Model of functional interactions for
proteoglycans and GAG after skin injury.
Table I. Binding interactions of glycosaminoglycans
(partial listings)
GAG Ligands
Heparan sulfate Extracellular matrix molecules
Collagen types I, III, IV, V, Fibronectin, Laminin,
Pleiotropin, Tenascin, Thrombospondin, wnt-I
Growth factors and cytokines
Fibroblast GF family, Hepatocyte GF/scatter factor,
Heparin-binding epidermal GF, Platelet-derived
GF, VEGF, IL-8, IP-10, HARP
Enzymes and enzyme inhibitors
Elastase, Thrombin, Tissue plasminogen activator,
Lipoprotein Lipase, Antithrombin III, Heparin
cofactor II, Leuserpin, Plasminogen activator
inhibitor-I, Protease nexin I
Chondroitin sulfates Laminin, Interferon-g, Platelet factor-4, Hepatocyte
GF, FGF-2
Complement protein Clq, Apo B, LDL
Hyaluronic acid CD-44, RHAMM, ICAM-1
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soluble environment of the wound demonstrates that endothelial
cells in this system can be affected by proteoglycans synthesized by
distant cells. One consequence of this observation is that release of
distant proteoglycans causes endothelial cells in the wound to
respond to proteoglycans in a manner that would not have been
predicted by experiments designed exclusively in an in vitro system.
For example, despite in vitro work that has shown FGF-2 activity is
in¯uenced by heparan sulfate, FGF-2 responsiveness to GAG
puri®ed from wound ¯uids is most dependent on the presence of
dermatan sulfate that is derived from the extracellular matrix
produced by dermal ®broblasts (Penc et al, 1998).
Observations such as those discussed above show that the
regulation of proteoglycans in the wound environment will depend
on several distinct processes and that the proteoglycan or GAG can
have activity as a soluble paracrine factor. To understand these
paracrine effects, further information about the synthesis and
processing of the GAG is necessary. Currently, rapid advances are
being made in the identi®cation of mammalian enzymes involved
in GAG synthesis and degredation. Enzymes such as the hapluronic
acid synthetases (Weigel et al, 1997), sulfotransferases (Falany,
1997), and mammalian heparanases have now been cloned (Hulett
et al, 1999) and provide tools for the study of select steps in
biosynthesis and degredation. Regulation of proteoglycan core
protein expression is incompletely understood, although syndecan-
1 expression can be in¯uenced by select growth factors such as
PDGF or FGF-2 and TGF-b. Additionally, an intriguing link
between immune defense and proteoglycan regulation was revealed
with the discovery that antimicrobial peptides in wounds can also
stimulate ®broblasts and endothelia to increase synthesis of
proteoglycans (Gallo et al, 1994).
GAG AS MODULATORS OF IMMUNE DEFENSE
The extensive repitoir of molecules that bind to GAG includes
several cytokines that play important roles during in¯ammation.
Associations between proteoglycan expression and in¯ammation
have been seen in adult and fetal wound repair as well as in a large
body of literature that has described the release of GAG with
various forms of collagen vascular disease. In these examples the
presence of GAG or proteoglycan can either enable soluble pro-
in¯ammatory molecules to function, or simply re¯ect an
epiphenomenon of in¯ammation. Furthermore, it is now apparent
that GAG can directly interact with endothelial cells to activate
in¯ammatory events. Two GAG have been identi®ed with the
potential for this interaction. Dermatan sulfate, isolated from
wounds, activates nuclear translocation of NF-kB in dermal
microvascular endothelial cells. Subsequent to the activation of
NF-kB, the expression of adhesion molecules such as ICAM-1,
VCAM, and E-Selectin all increase (Penc et al, 1999). Hyaluronan
can induce VCAM on renal tubular epithelial cells (Oertli et al,
1998) as well as in¯uence the function of macrophages by
increasing the synthesis of metalloelastase, nitric oxide synthase,
chemokines, and plasminogen activator inhibitor-1 (Horton et al,
1999a,b). In this case, fragments of the HA appear to be most
active. Thus, activity of a hyaluronidase on previously made
hyaluronan will activate this system.
Finding that GAG have activity as a paracrine signalling molecule
has important implications toour understandingof vascular biology in
a complex tissue such as the skin. The example of wound repair
illustrates a model for understanding the critical and central role
proteoglycans play in regulating a variety of cell processes (Fig 4).
Following tissue injury cells at the site respond by increasing
proteolysis and GAG degradation to release soluble proteoglycans
and GAG fragments. Simultaneously, antimicrobial peptides provide
an early innate defense system protecting against rapid bacterial
proliferation in the wound and also stimulate proteoglycan synthesis.
The increase in GAG fragments, proteoglycans, and soluble
proteoglycans each can then in¯uence events involved in cell growth
and division. Furthermore, these molecules also promote in¯amma-
tion, and through stimulation of adhesion molecule expression will
lead to enhanced cellular innate defense of the wound.
FUTURE DIRECTIONS
A major challenge faced by investigators in the ®eld of proteoglycan
biology is to test the many hypotheses that have developed from
experiments performed in vitro. As more parts of the system are
de®ned we recognize greater redundancy and the capacity of this
complex system to accommodate a change in a single component.
New information provides many opportunities to investigate the
therapeutic potential of manipulating steps in proteoglycan
processing. Additional components of the GAG and proteoglycan
system must be identi®ed, and with this knowledge molecules
designed to in¯uence their function. Given our current level of
understanding it is likely that through an increased understanding of
proteoglycans we will be able to exert a positive in¯uence on
vascular biology.
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